Basit öğe kaydını göster

dc.contributor.authorBatırel, Ayşe
dc.contributor.authorGüçlü, Ertuǧrul
dc.contributor.authorArslan, Ferhat
dc.contributor.authorKoçak, Funda
dc.contributor.authorKarabay, Oğuz
dc.contributor.authorÖzer, Serdar
dc.contributor.authorTuranlı, Münevver
dc.contributor.authorMert, Ali
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:35:52Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:35:52Z
dc.date.issued2014en_US
dc.identifier.citationBatırel, A., Güçlü, E., Arslan, F., Koçak, F., Karabay, O., Özer, S., Turanlı, M. ve Mert, A. (2014). Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: A multicenter real-life study. International Journal of Infectious Diseases, 28, 153-159. https://dx.doi.org/10.1016/j.ijid.2014.09.004en_US
dc.identifier.issn1201-9712
dc.identifier.urihttps://dx.doi.org/10.1016/j.ijid.2014.09.004
dc.identifier.urihttps://hdl.handle.net/20.500.12511/974
dc.description.abstractObjective: To compare responses to tenofovir (TDF) and entecavir (ETV) therapy. Methods: This was a multicenter retrospective study including treatment-naïve patients with chronic hepatitis B (CHB) who received TDF or ETV. The primary end-points were undetectable HBV-DNA at 48 weeks and serological and biochemical responses. Results: Out of 195 CHB patients, 90 (46%) received TDF and 105 (54%) received ETV; 72% were male, their mean age was 43. ±. 12 years, and the mean duration of treatment was 30.2. ±. 15.7 months. Hepatitis B e antigen (HBeAg) seropositivity was 32% in the TDF group and 34% in the ETV group. HBeAg seroconversion rates in HBeAg-positive patients were 24% in the TDF group and 39% in the ETV group; the difference was not significant (. p=. 0.2). The mean time to alanine aminotransferase (ALT) normalization and rates of ALT normalization at 3, 6, 12, 18, and 24 months were similar in the two groups (. p > 0.05). The mean time to undetectable HBV-DNA levels in the TDF and ETV groups was 11.5. ±. 8.9 and 12.9. ±. 10.8 months, respectively (. p=. 0.32). A significantly greater decline in HBV-DNA levels at 12 and 18 months was observed in the TDF group (. p=. 0.02 and p=. 0.03, respectively). Seven (7%) patients on ETV therapy had virological breakthrough (. p=. 0.01). Only one patient in each group had hepatitis B surface antigen (HBsAg) clearance. None of the patients developed decompensation or hepatocellular carcinoma during treatment. Conclusions: The two drugs appear to have similar efficacy in CHB patients. However, 7% of patients on ETV therapy had virological breakthrough, while none of the patients on TDF therapy did.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Unported*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/*
dc.subjectChronic Hepatitis Ben_US
dc.subjectEntecaviren_US
dc.subjectHBVen_US
dc.subjectTenofoviren_US
dc.subjectTreatmenten_US
dc.titleComparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: A multicenter real-life studyen_US
dc.typearticleen_US
dc.relation.ispartofInternational Journal of Infectious Diseasesen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalıen_US
dc.authorid0000-0001-8554-7651en_US
dc.authorid0000-0001-8945-2385en_US
dc.identifier.volume28en_US
dc.identifier.startpage153en_US
dc.identifier.endpage159en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.ijid.2014.09.004en_US
dc.identifier.wosqualityQ2en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess